Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Belmalip; Colemin; Denan; L-644128-000U; Lipex; Liponorm; Lipovas; Lodales; Medipo; MK-733; Pantok; Sinvacor; Sivastin; Synvinolin; Velastatin; Zocor; Zocord

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical University of South Carolina; Merck Sharp & Dohme
  • Developer Cystic Fibrosis Foundation Therapeutics; Medical University of South Carolina; Merck & Co; Merck Sharp & Dohme; Sahlgrenska University Hospital; University of Tokyo
  • Class Antihyperlipidaemics; Naphthalenes; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic cardiomyopathy; Hypercholesterolaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia; Low HDL cholesterol
  • No development reported Cystic fibrosis; Multiple sclerosis
  • Discontinued Alzheimer's disease; Bone resorption; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystic-fibrosis in USA (PO, Tablet)
  • 01 Mar 2017 University College London initiates the phase III MS-STAT2 trial for Multiple sclerosis in United Kingdom
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top